alan venook, md, discusses uniqueness of msi-high/mismatch repair deficient crc patients
Published 4 years ago • 45 plays • Length 3:08
Download video MP4
Download video MP3
Similar videos
-
1:47
alan venook, md discusses development of immunotherapies for non msi-high crc patients
-
1:39
alan venook, md, discusses next generation sequencing and mcrc treatment
-
17:17
mismatch repair (mmr) deficiency in colorectal cancer
-
1:44
alan venook, md, considers how immunotherapy is being integrated into crc treatment algorithms
-
2:03
alan venook, md, explains the biological difference between left-sided and right-sided crc tumors
-
1:30
alan venook, md, discusses vemurafenib and the nccn guidelines for mcrc patients
-
1:17
alan p. venook, md, discusses which molecular tests to order for a newly diagnosed crc patient
-
1:54
alan venook, md, explains how tumor sidedness affects therapeutic choice
-
52:45
current treatment options - stephen ansell, md
-
3:52
stage 2 colon cancer diagnosis story
-
23:10
genetic testing and next generation dna sequencing in prostate cancer
-
2:12
alan venook, md, considers how i-o is evolving towards the first line treatment of colorectal cancer
-
1:23
dr. venook on immunotherapy potential in colorectal cancer
-
2:16
alan venook, md, on potential new standard in care post approval of atezolizumab bevacizumab
-
1:03
dr. venook on looking ahead at treatment for crc
-
1:05
alan p. venook, md, on integrating immunotherapy into treatment regimens for gastric cancer patients
-
2:56
current state of molecular testing for metastatic crc
-
4:28
mismatch repair deficiency may play a role in the development of colorectal cancer
-
1:18
alan venook, md, on the latest in identifying valid biomarkers in the treatment of hcc
-
10:06
understanding tumor sidedness in colorectal cancer
-
2:59
alan venook, md, provides opinions of the opra data in rectal cancer patients presented at asco20
-
1:11
alan venook, md, tells us whether ctdna is a valid treatment response in crc
Clip.africa.com - Privacy-policy